English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims  To evaluate the efficacy and safety of dulaglutide 1.5 and 0.75 mg in elderly patients (aged ≥65 years) with type 2 diabetes ( T2D ) in six phase  III  clinical trials.    Methods  Patients were grouped into two age groups: ≥65 and <65 years. Pooled analysis for glycated haemoglobin ( HbA1c ) change from baseline, percentage of patients achieving  HbA1c  targets, and gastrointestinal tolerability were evaluated at 26 weeks for each dulaglutide dose. Change in weight from baseline and rates of hypoglycaemia were evaluated for each individual study.    Results  A total of 958 of 5171 (18.5%) patients were aged ≥65 years. The reductions in  HbA1c  were similar between age groups for dulaglutide 1.5 mg‐treated patients {least squares [ LS ] mean for patients aged ≥65 years: −1.24 [95% confidence interval ( CI ) −1.36, −1.12] and for patients aged <65 years: −1.29 [95%  CI  −1.38, −1.20]} and for dulaglutide 0.75 mg‐treated patients [ LS  mean for patients aged ≥65 years: −1.16 (95%  CI  −1.29, −1.03) and for patients aged <65 years: −1.10 (95%  CI  −1.19, −1.01)] at 26 weeks. The percentages of patients who achieved  HbA1c  targets of <7, <8 or <9% were also similar in the two groups with both dulaglutide doses. Patients aged ≥65 years had similar weight change to patients aged <65 years. Severe hypoglycaemic events were infrequent. A similar incidence of gastrointestinal adverse events was observed in each age group with both dulaglutide doses.    Conclusion  Both dulaglutide doses were well tolerated, with similar efficacy in patients with  T2D  aged ≥65 years to those aged <65 years. Dulaglutide can be considered a safe and effective treatment option for use in older adults.

Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years